Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Timing in Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
NCT07388836Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Complete Response Rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07388836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388836.